Broadwood Partners Plans to Vote Against Staar Sale to Alcon
I'm PortAI, I can summarize articles.
Broadwood Partners, holding 27.3% of Staar Surgical, plans to vote against the company's sale to Alcon, citing concerns over the sale process and Staar's growth potential. They argue that Staar did not adequately pursue the sale and faced issues regarding access to records. Staar defends the deal, highlighting a 51% premium to its recent closing price and asserting that the $28-per-share offer exceeds potential standalone value, despite challenges in the market, particularly in China.
Source: MorningStar The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments